In conclusion, Boennuokang® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy achieves reduced PSA, testosterone, and prostate volume, and low positive surgical margin rate in patients with high-risk prostate cancer. Here, KLK3 is linked to prostate carcinoma.